Product Number : 68782-001-02
Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration.
After one year of treatment, about 70% of the patients treated with Macugen 0.3 and 1 mg lost less than 15 letters in the eye test compared with about 55% of those who received the sham injection.
The 3-mg dose did not bring any additional benefit. This improvement lasted for two years in patients who were given Macugen.